Human anti-Varicella zoster virus (VZV) gE IgM, Recombinant

Recombinant human anti-Varicella zoster virus VZV gE (clone M1410) IgM antibody, purified by ion exchange chromatography, ammonium sulphate precipitation and dialysis.

PRODUCT DETAILS – Human anti-Varicella zoster virus (VZV) gE IgM, Recombinant

• Isotype: human IgM
• Clone Number: M1410
• Presented as Liquid in 50mM HEPES, 150mM NaCl, pH8.0

BACKGROUND

Varicella‑zoster virus (VZV) is an exclusively human, neurotropic alphaherpesvirus that causes varicella during primary infection and herpes zoster upon reactivation from latency in sensory ganglia, with disease burden concentrated in older or immunocompromised individuals. The viral envelope displays multiple glycoproteins, including glycoproteins E (gE), B (gB), and H/L (gH/gL), which are major targets of the humoral response and play essential roles in virion fusion, entry, and cell‑to‑cell spread (Sullivan et al., 2018). Functional studies using monoclonal antibodies have shown that gH/gL and gB are minimally sufficient for VZV fusion, and that anti‑gH monoclonal antibodies can potently neutralize virus and inhibit cell‑to‑cell infection while modulating glycoprotein distribution in infected cells (Shiraki et al., 2011).

Recombinant VZV antibodies provide a renewable, well‑defined alternative to conventional hybridoma‑derived monoclonals for dissecting these glycoprotein‑specific responses (Birlea et al., 2013; Sullivan et al., 2018). Human recombinant monoclonal antibodies isolated after Zostavax vaccination have been shown to recognize conformational epitopes within the gH/gL complex and to neutralize VZV infection in vitro (Birlea et al., 2013), enabling detailed analyses of membrane fusion mechanisms and epitope specificity. Together with assays based on recombinant gE ectodomain, such as indirect ELISAs for detecting anti‑VZV antibodies in clinical samples (Niu et al., 2022), these reagents underpin modern serology, vaccine evaluation, and the rational engineering of antibodies with optimized specificity and effector function for diagnostic and potential therapeutic applications (Sullivan et al., 2018).

REFERENCES

Birlea M et al. Human anti varicella zoster virus (VZV) recombinant monoclonal antibody produced after Zostavax immunization recognizes the gH/gL complex and neutralizes VZV infection. J Virol. 2013

Sullivan NL et al. Breadth and functionality of varicella zoster virus glycoprotein specific antibodies identified after Zostavax vaccination in humans. J Virol. 2018.

Shiraki K et al. Neutralizing anti gH antibody of varicella zoster virus modulates distribution of gH and induces gene regulation, mimicking latency. J Virol. 2011.

Niu Y et al. Development of an indirect ELISA kit for rapid detection of varicella zoster virus antibody by glycoprotein E. Front Microbiol. 2022.